WO2005118813A3 - Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein - Google Patents

Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein Download PDF

Info

Publication number
WO2005118813A3
WO2005118813A3 PCT/EP2005/006512 EP2005006512W WO2005118813A3 WO 2005118813 A3 WO2005118813 A3 WO 2005118813A3 EP 2005006512 W EP2005006512 W EP 2005006512W WO 2005118813 A3 WO2005118813 A3 WO 2005118813A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
methods
immunogenic compositions
expression
nucleic acids
Prior art date
Application number
PCT/EP2005/006512
Other languages
French (fr)
Other versions
WO2005118813A2 (en
Inventor
Ralf Altmeyer
Beatrice Nal-Rogier
Cheman Chan
Francois Kien
Yiu Wing Kam
Yu Lam Siu
Kong San Tse
Isabelle Staropoli
Jean-Claude Manuguerra
Original Assignee
Pasteur Institut
Hong Kong Pasteur Res Ct Ltd
Ralf Altmeyer
Beatrice Nal-Rogier
Cheman Chan
Francois Kien
Yiu Wing Kam
Yu Lam Siu
Kong San Tse
Isabelle Staropoli
Jean-Claude Manuguerra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Hong Kong Pasteur Res Ct Ltd, Ralf Altmeyer, Beatrice Nal-Rogier, Cheman Chan, Francois Kien, Yiu Wing Kam, Yu Lam Siu, Kong San Tse, Isabelle Staropoli, Jean-Claude Manuguerra filed Critical Pasteur Institut
Priority to EP05750800A priority Critical patent/EP1751178A2/en
Priority to CA002568838A priority patent/CA2568838A1/en
Publication of WO2005118813A2 publication Critical patent/WO2005118813A2/en
Publication of WO2005118813A3 publication Critical patent/WO2005118813A3/en
Priority to US11/635,822 priority patent/US20070190065A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Nucleic acid molecules, polypeptides, immunogenic compositions, vaccines, and methods of making and using the nucleotides and encoded polypeptides associated with the Spike protein of SARS Corona Virus (SARS CoV) are disclosed.
PCT/EP2005/006512 2004-06-04 2005-06-03 Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein WO2005118813A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP05750800A EP1751178A2 (en) 2004-06-04 2005-06-03 Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein
CA002568838A CA2568838A1 (en) 2004-06-04 2005-06-03 Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein
US11/635,822 US20070190065A1 (en) 2005-06-03 2006-12-04 Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with SARS corona virus spike protein

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86064104A 2004-06-04 2004-06-04
US10/860,641 2004-06-04
US57834804P 2004-06-10 2004-06-10
US60/578,348 2004-06-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/635,822 Continuation US20070190065A1 (en) 2005-06-03 2006-12-04 Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with SARS corona virus spike protein

Publications (2)

Publication Number Publication Date
WO2005118813A2 WO2005118813A2 (en) 2005-12-15
WO2005118813A3 true WO2005118813A3 (en) 2006-03-16

Family

ID=35463454

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/006512 WO2005118813A2 (en) 2004-06-04 2005-06-03 Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein

Country Status (3)

Country Link
EP (1) EP1751178A2 (en)
CA (1) CA2568838A1 (en)
WO (1) WO2005118813A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7022969B2 (en) 2020-02-19 2022-02-21 ユーロイミューン・メディツィニシェ・ラボルディアグノシュティカ・アクチエンゲゼルシャフト Methods and Reagents for Diagnosing SARS-CoV-2 Infections

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007010399A2 (en) * 2005-06-28 2007-01-25 HKU-PASTEUR RESEARCH CENTRE LIMITED Dexter HC Man Building Purified trimeric s protein as vaccine against severe acute respiratory syndrome virus infections
GB0711858D0 (en) * 2007-06-19 2007-07-25 Glaxosmithkline Biolog Sa Vaccine
US20160238601A1 (en) * 2013-10-14 2016-08-18 The University Of North Carolina At Chapel Hill Methods and compositions for coronavirus diagnostics and therapeutics
EP4349404A3 (en) 2015-10-22 2024-06-19 ModernaTX, Inc. Respiratory virus vaccines
PL3869199T3 (en) * 2020-02-20 2022-05-30 Euroimmun Medizinische Labordiagnostika Ag A method and reagents for the diagnosis of sars-cov-2
WO2021186029A1 (en) * 2020-03-20 2021-09-23 Deutsches Krebsforschungszentrum Sars spike peptides and uses thereof
WO2021184391A1 (en) * 2020-03-20 2021-09-23 广州市康润生物科技有限公司 Method for earlier screening of novel coronavirus
CA3142132C (en) * 2020-03-30 2024-06-04 Variation Biotechnologies Inc. Vaccine compositions for the treatment of coronavirus
WO2021223647A1 (en) * 2020-05-06 2021-11-11 The University Of Hong Kong Compositions and methods for making and using vaccines against covid-19
DE20175031T1 (en) 2020-05-15 2021-09-09 Euroimmun Medizinische Labordiagnostika Ag Method for determining the effectiveness of a SARS-CoV-2 vaccine
CN114072422B (en) * 2020-06-04 2022-06-21 山东博安生物技术股份有限公司 Neutralizing antibody of SARS-CoV-2 virus and its application
WO2021249010A1 (en) * 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus diagnostic compositions, methods, and uses thereof
WO2021254476A1 (en) * 2020-06-19 2021-12-23 南京金斯瑞生物科技有限公司 Magnetic microparticle chemiluminescence reagent kit for detecting sars-cov-2 virus neutralising antibodies and application therefor
DE102020125915B3 (en) 2020-10-02 2022-03-03 Institut für Molekulare Diagnostik und Bioanalytik IMMUNDIAGNOSTIC MEANS AND METHODS FOR DETECTION AND DIFFERENTIATION OF CORONAVIRUS INFECTIONS
WO2022224271A1 (en) * 2021-04-19 2022-10-27 Bharat Serums And Vaccines Limited Polyclonal antibodies against sars-cov-2 and implementations thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004110483A1 (en) * 2003-05-31 2004-12-23 Yiyou Chen Method and composition of a novel vaccine design for the prevention and treatment of sars
WO2005012360A2 (en) * 2003-07-22 2005-02-10 Crucell Holland B.V. Binding molecules against sars-coronavirus and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004110483A1 (en) * 2003-05-31 2004-12-23 Yiyou Chen Method and composition of a novel vaccine design for the prevention and treatment of sars
WO2005012360A2 (en) * 2003-07-22 2005-02-10 Crucell Holland B.V. Binding molecules against sars-coronavirus and uses thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE UniProt [online] 10 October 2003 (2003-10-10), "Spike glycoprotein precursor (Peplomer protein) (E2) [Contains: Spike protein S1; Spike protein S2].", XP002361176, retrieved from EBI accession no. UNIPROT:SPIKE_CVHSA Database accession no. SPIKE_CVHSA *
FENG GAO ET AL: "CODON USAGE OPTIMIZATION OF HIV TYPE 1 SUBTYPE C GAG, POL, ENV, AND NEF GENES: IN VITRO EXPRESSION AND IMMUNE RESPONSES IN DNA-VACCINATED MICE", AIDS RESEARCH AND HUMAN RETROVIRUSES, MARY ANN LIEBERT, US, vol. 19, no. 9, 2003, pages 817 - 823, XP009025628, ISSN: 0889-2229 *
GURUNATHAN S ET AL: "DNA vaccines: immunology, application, and optimization*", ANNUAL REVIEW OF IMMUNOLOGY, ANNUAL REVIEWS INC, US, vol. 18, 2000, pages 927 - 974, XP009019110, ISSN: 0732-0582 *
HO T-Y ET AL: "Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 313, no. 4, 23 January 2004 (2004-01-23), pages 938 - 947, XP004482920, ISSN: 0006-291X *
MARRA M A ET AL: "The genome sequence of the SARS-associated coronavirus", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 300, no. 5624, 30 May 2003 (2003-05-30), pages 1399 - 1404, XP002269483, ISSN: 0036-8075 *
STADLER KONRAD ET AL: "SARS - Beginning to understand a new virus", NATURE REVIEWS MICROBIOLOGY, vol. 1, no. 3, December 2003 (2003-12-01), pages 209 - 218, XP009059463, ISSN: 1740-1526 *
ZHI Y ET AL: "Identification of murine CD8 T cell epitopes in codon-optimized SARS-associated coronavirus spike protein", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 335, no. 1, 25 April 2005 (2005-04-25), pages 34 - 45, XP004844952, ISSN: 0042-6822 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7022969B2 (en) 2020-02-19 2022-02-21 ユーロイミューン・メディツィニシェ・ラボルディアグノシュティカ・アクチエンゲゼルシャフト Methods and Reagents for Diagnosing SARS-CoV-2 Infections

Also Published As

Publication number Publication date
WO2005118813A2 (en) 2005-12-15
EP1751178A2 (en) 2007-02-14
CA2568838A1 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
WO2005118813A3 (en) Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein
WO2006104615A3 (en) Influenza nucleic acids, polypeptides, and uses thereof
WO2006002038A3 (en) Immunostimulatory oligonucleotide multimers
WO2005017101A3 (en) Avian adenoassociated virus (aaav) and uses thereof
WO2007050095A3 (en) Improved vaccines and methods for using the same
WO2005056759A3 (en) Methods of generating variant proteins with increased host string content and compositions thereof
EP1989316A4 (en) Method for the production of recombinant virus, dna constructs, recombinant virus and vaccine compositions
WO2005003296A3 (en) Albumin fusion proteins
WO2007110231A3 (en) MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
WO2008028117A3 (en) Glp-2 mimetibodies, polypeptides, compositions, methods and uses
WO2007067828A3 (en) Glp-2 mimetibodies, polypeptides, compositions, methods and uses
EP2351843A3 (en) Rabies virus vector systems and compositions and methods thereof
WO2004031210A3 (en) Optimized multi-epitope constructs and uses thereof
WO2007087053A3 (en) Bmp-7 variant compositions, methods and uses
WO2006047728A3 (en) Bmp gene and fusion protein
WO2007045019A3 (en) Polyoleosins
AU2003216184A1 (en) Nucleic acid molecules encoding cd1-derived endosomal targeting proteins and uses thereof
WO2005011571A3 (en) Hepatitis virus core proteins as vaccine platforms and methods of use thereof
WO2005013904A3 (en) Sars nucleic acids, proteins, vaccines, and uses thereof
WO2005033265A3 (en) Optimized multi-epitope constructs and uses thereof
WO2007010399A3 (en) Purified trimeric s protein as vaccine against severe acute respiratory syndrome virus infections
WO2006081463A3 (en) Thermococcus zilligii dna polymerases and variants thereof
WO2006073627A3 (en) Vaccinia virus nucleic acids, polypeptides, and immunogenic compositions
WO2008014054A3 (en) Bmp-7 variant compositions, methods and uses
EP1937717A4 (en) Penumbra nucleic acid molecules, proteins and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2568838

Country of ref document: CA

Ref document number: 7271/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 11635822

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005750800

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200580026090.0

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005750800

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11635822

Country of ref document: US